Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Income from Continuing Operations (2020 - 2025)

Foghorn Therapeutics has reported Income from Continuing Operations over the past 6 years, most recently at 22166000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 22166000.0 for Q4 2025, down 13.65% from a year ago — trailing twelve months through Dec 2025 was 77644000.0 (up 10.36% YoY), and the annual figure for FY2025 was 77644000.0, up 10.36%.
  • Income from Continuing Operations for Q4 2025 was 22166000.0 at Foghorn Therapeutics, down from 16469000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for FHTX hit a ceiling of 14345000.0 in Q3 2023 and a floor of 30488000.0 in Q1 2023.
  • Median Income from Continuing Operations over the past 5 years was 23931000.0 (2021), compared with a mean of 23710600.0.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 68.9% in 2021 and later skyrocketed 44.33% in 2023.
  • Foghorn Therapeutics' Income from Continuing Operations stood at 28508000.0 in 2021, then dropped by 1.33% to 28886000.0 in 2022, then increased by 16.55% to 24106000.0 in 2023, then grew by 19.09% to 19503000.0 in 2024, then fell by 13.65% to 22166000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 22166000.0 (Q4 2025), 16469000.0 (Q3 2025), and 18788000.0 (Q2 2025) per Business Quant data.